LFGVX
Price
$42.67
Change
+$0.05 (+0.12%)
Updated
Sep 5 closing price
Net Assets
157.05M
RGEBX
Price
$82.44
Change
+$0.19 (+0.23%)
Updated
Sep 5 closing price
Net Assets
331.65B
Interact to see
Advertisement

LFGVX vs RGEBX

Header iconLFGVX vs RGEBX Comparison
Open Charts LFGVX vs RGEBXBanner chart's image
Lord Abbett Focused Growth R6
Price$42.67
Change+$0.05 (+0.12%)
VolumeN/A
Net Assets157.05M
American Funds Growth Fund of Amer R2E
Price$82.44
Change+$0.19 (+0.23%)
VolumeN/A
Net Assets331.65B
LFGVX vs RGEBX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
LFGVX vs. RGEBX commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LFGVX is a StrongBuy and RGEBX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RGEBX has more cash in the bank: 332B vs. LFGVX (157M). LFGVX (0.00) and RGEBX (0.00) have matching dividends . LFGVX was incepted earlier than RGEBX: LFGVX (7 years) vs RGEBX (11 years). LFGVX (1.10) and RGEBX (1.09) have similar cost to investors . LFGVX is a more actively managed with annual turnover of: 122.00 vs. RGEBX (25.00). LFGVX has a lower initial minimum investment than RGEBX: LFGVX (0) vs RGEBX (250). LFGVX annual gain was more profitable for investors over the last year : 47.27 vs. RGEBX (17.32). LFGVX return over 5 years is better than : 60.41 vs. RGEBX (38.39).
LFGVXRGEBXLFGVX / RGEBX
Total Expense Ratio0.701.0964%
Annual Report Gross Expense Ratio1.101.09101%
Fund Existence7 years11 years-
Gain YTD14.81715.13298%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets157M332B0%
Annual Yield % from dividends0.000.00-
Returns for 1 year47.2717.32273%
Returns for 3 years106.6957.24186%
Returns for 5 years60.4138.39157%
Returns for 10 yearsN/A91.00-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARTV3.610.50
+16.08%
Artiva Biotherapeutics Inc
ARCT17.851.09
+6.50%
Arcturus Therapeutics Holdings
MANH215.315.45
+2.60%
Manhattan Associates
TRMD23.020.25
+1.10%
TORM plc
INDP3.30-1.31
-28.35%
Indaptus Therapeutics Inc